GUTS Fractyl Health, Inc. Common Stock Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
16:36
Jan 29
A May MD Biotech investor
Speaker sets a reminder, no directional view or position stated.
GUTS
LOW
06:15
Jan 20
Grant Beaty Software dev & racecar driver turned L/S fund manager
Short GUTS on gene therapy execution risk — transduction variability across cell lines, genes, health status, injection sites, and AAV neutralizing antibodies creates unpredictable dosing outcomes; β-cell longevity means adverse effects (perma-nausea) could be permanent, driving patients toward alternatives and undermining commercial viability.
GUTS 1ST
MED

About GUTS Analyst Coverage

Buzzberg tracks GUTS (Fractyl Health, Inc. Common Stock) across 2 sources. 0 bullish vs 1 bearish calls from 2 analysts. Sentiment: mixed to bearish. 2 total trade ideas tracked. Latest voices: A May MD, Grant Beaty.